Prima BioMed (PBMD) Immunotherapy Delivery Method Looks Promising - Maxim Group

Maxim Group analyst, Jason McCarthy, reiterated his Buy rating on Prima Biomed (NASDAQ: PBMD) after Prima announced a collaboration with the Institute of Clinical Cancer Research at Krankenhaus Nordwest GmbH in Germany ("IKF") to evaluate the potential of using intra-tumoral delivery of IMP321 (LAG-3Ig fusion protein) to activate immune responses against solid tumors.

Delivery of immunotherapy directly to (intra-tumoral) or in the area of tumors (intra-peritoneal) are attractive approaches that may circumvent tumor defenses and the tumor micro-environment, which is often hostile towards immune cells. Oncosec (NASDAQ: ONCS) and Inovio (NASDAQ: INO) use this approach to deliver DNA-based immunotherapies via electroporation and Celsion (NASDAQ: CLSN) uses intra-peritoneal delivery for its DNA-based IL-12, each has shown promising data thus far...Prima's LAG-3, IMP321, could be next.

No change to the Buy rating or price target of $5.00

For an analyst ratings summary and ratings history on Prima Biomed click here. For more ratings news on Prima Biomed click here.

Shares of Prima Biomed closed at $0.92 yesterday.

You May Also Be Interested In

• Jefferies Upgrades Husqvarna AB (HUSQB:SS) to Buy
• Amazon.com (AMZN) PT Raised to $215 at UBS
• Tantech Holdings (TANH) Announces $2.1 Million Private Placement